Merck Pulls EPS Guidance To Avoid "Indiscriminate Short-Term Cost Cutting"
This article was originally published in The Pink Sheet Daily
Executive Summary
In Kenneth Frazier's first financial call as CEO, the exec withdrew Merck's long-term earnings guidance, citing healthcare reform costs, European pricing pressure and a late-stage pipeline setback.
You may also be interested in...
Business and Finance News, In Brief
Oral Treprostinil Meets Phase III Endpoint
Business and Finance News, In Brief
Oral Treprostinil Meets Phase III Endpoint
For Pfizer Chief, The First Order Of Business Is Research
In Read's first presentation to investors, the new chief executive laid out plans to reorganize research as part of a strategy to improve productivity and cut spending by $1.5 billion in 2012.